En Carta Diagnostics Raises €5 Mn in Round

The funding includes €3 million in equity investment, led by Blue Forest Ventures.

Other investors in the round include Ring Capital, existing investor CentraleSupélec Venture, 50 Partners Health, and a group of business angels.

The round also includes €2 million in non-dilutive funding from Bpifrance and other partners. Earlier, in May 2024, the company raised €1.5 million in pre-seed funding, led by CentraleSupélec Venture.

“This first closing brings us closer to our mission of transforming access to testing. By enabling patients to perform reliable molecular tests wherever they are, we can support earlier diagnosis, improve patient outcomes and help relieve pressure on healthcare systems,” said Guillaume Horreard, co-founder and CEO, En Carta Diagnostics.

“It uses aptamers, capable of binding with high affinity and specificity to a predetermined target. This ‘signature’ can be programmed to detect any genetic, pathogenic or veterinary indication opening an extensive range of applications,” En Carta explained.

“From FDA Breakthrough Designation to a €13 million commercial partnership, and now €5 million in financing, En Carta is delivering. Our next milestone is getting our two products, a rapid molecular diagnostic for Borrelia, the bacteria responsible for Lyme disease, and an STI screening test, into the hands of patients and clinicians across Europe and the US,” added Horreard.

Founded in 2022 by Horreard and Margot Karlikow, En Carta Diagnostics is developing a new generation of molecular diagnostic tests that people can use at home. The company aims to provide accurate and easy-to-use health testing.

Its technology combines the high accuracy of a laboratory PCR test with the simplicity and convenience of a rapid test.

The company says its own diagnostic platform makes advanced molecular testing available wherever patients are, without the need to visit a laboratory or use complex lab equipment.